KRAS and non-small cell lung carcinoma: To test the efficacy of active immunotherapy through DNA electrovaccination against ROS1-positive NSCLC, we exploited transgenic mice that harbor a latent oncogenic K-Ras allele, at the endogenous locus, that is capable of spontaneous activation in vivo, due to an activating mutation at codon 12 (K-RasG12D mice).